Consolidated Statements of Cash Flows (USD $) In Thousands	6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010
BIOMED REALTY TRUST, INC. [Member]
Operating activities:
Net income	$ 17,824	$ 17,196
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	69,625	55,385
Allowance for doubtful accounts	931	254
Non-cash revenue adjustments	5,145	(796)
Other non-cash adjustments	6,621	7,805
Compensation expense related to restricted common stock and LTIP units / share-based payments	3,656	3,514
Distributions representing a return on capital from unconsolidated partnerships	816	860
Changes in operating assets and liabilities:
Restricted cash	3,357	3,808
Accounts receivable	2,715	1,022
Accrued straight-line rents	(10,249)	(14,232)
Deferred leasing costs	(9,402)	(1,740)
Other assets	524	(10,355)
Security deposits	(339)	705
Accounts payable, accrued expenses and other liabilities	(9,452)	5
Net cash provided by operating activities	81,772	63,431
Investing activities:
Purchases of interests in and additions to investments in real estate and related intangible assets	(120,518)	(155,247)
Purchases of equity securities	(2,050)
Proceeds from the sale of equity securities		1,227
Funds held in escrow for acquisitions		(18,378)
Net cash used in investing activities	(122,568)	(172,398)
Financing activities:
Proceeds from common stock offering		243,931
Payment of common stock offering costs		(9,744)
Payment of deferred loan costs	(3,378)	(8,402)
Unsecured line of credit proceeds	145,475	229,142
Unsecured line of credit payments	(416,725)	(456,308)
Principal payments on mortgage notes payable	(33,268)	(3,647)
Secured term loan repayments		(250,000)
Repurchases of exchangeable senior notes due 2026		(24,306)
Proceeds from exchangeable senior notes due 2030		180,000
Proceeds from unsecured senior notes	397,460	247,442
Deferred settlement payments on interest rate swaps, net	(88)	(485)
Distributions to operating partnership unit and LTIP unit holders	(1,107)	(857)
Dividends paid to common stockholders/unitholders	(48,526)	(27,901)
Dividends paid to preferred stockholders/unitholders	(8,481)	(8,481)
Net cash provided by financing activities	31,362	110,384
Net (decrease)/increase in cash and cash equivalents	(9,434)	1,417
Cash and cash equivalents at beginning of period	21,467	19,922
Cash and cash equivalents at end of period	12,033	21,339
Supplemental disclosure of cash flow information:
Cash paid during the period for interest (net of amounts capitalized of $3,311 and $2,946, respectively)	35,927	33,330
Supplemental disclosure of non-cash investing and financing activities:
Accrual for preferred stock/unit dividends/distributions declared	4,241	4,241
Accrual for common stock/unit dividends/distributions declared	26,252	17,037
Accrual for distributions declared for operating partnership unit and LTIP unit holders	596	450
Accrued additions to real estate and related intangible assets	26,691	13,357
BIOMED REALTY, L.P. [Member]
Operating activities:
Net income	17,824	17,196
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	69,625	55,385
Allowance for doubtful accounts	931	254
Non-cash revenue adjustments	5,145	(796)
Other non-cash adjustments	6,621	7,805
Compensation expense related to restricted common stock and LTIP units / share-based payments	3,656	3,514
Distributions representing a return on capital from unconsolidated partnerships	816	860
Changes in operating assets and liabilities:
Restricted cash	3,357	3,808
Accounts receivable	2,715	1,022
Accrued straight-line rents	(10,249)	(14,232)
Deferred leasing costs	(9,402)	(1,740)
Other assets	524	(10,355)
Security deposits	(339)	705
Accounts payable, accrued expenses and other liabilities	(9,452)	5
Net cash provided by operating activities	81,772	63,431
Investing activities:
Purchases of interests in and additions to investments in real estate and related intangible assets	(120,518)	(155,247)
Purchases of equity securities	(2,050)
Proceeds from the sale of equity securities		1,227
Funds held in escrow for acquisitions		(18,378)
Net cash used in investing activities	(122,568)	(172,398)
Financing activities:
Proceeds from issuance of OP units		234,187
Payment of deferred loan costs	(3,378)	(8,402)
Unsecured line of credit proceeds	145,475	229,142
Unsecured line of credit payments	(416,725)	(456,308)
Principal payments on mortgage notes payable	(33,268)	(3,647)
Secured term loan repayments		(250,000)
Repurchases of exchangeable senior notes due 2026		(24,306)
Proceeds from exchangeable senior notes due 2030		180,000
Proceeds from unsecured senior notes	397,460	247,442
Deferred settlement payments on interest rate swaps, net	(88)	(485)
Dividends paid to common stockholders/unitholders	(49,633)	(28,758)
Dividends paid to preferred stockholders/unitholders	(8,481)	(8,481)
Net cash provided by financing activities	31,362	110,384
Net (decrease)/increase in cash and cash equivalents	(9,434)	1,417
Cash and cash equivalents at beginning of period	21,467	19,922
Cash and cash equivalents at end of period	12,033	21,339
Supplemental disclosure of cash flow information:
Cash paid during the period for interest (net of amounts capitalized of $3,311 and $2,946, respectively)	35,927	33,330
Supplemental disclosure of non-cash investing and financing activities:
Accrual for preferred stock/unit dividends/distributions declared	26,848	17,487
Accrual for common stock/unit dividends/distributions declared	4,241	4,241
Accrued additions to real estate and related intangible assets	$ 26,691	$ 13,357